Alzamend Neuro, Inc. (NASDAQ: ALZN) announced that pharmacokinetic imaging data from its Phase 1/2A clinical trial of AL001, an organic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE